Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Industry: Healthcare

OFF LIST - 2389 consecutive market days: OFF LIST as of 12/07/2006 Through 11/14/2016

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for intravenous administration in systemic indications. It has a risk-sharing collaboration agreement with SFJ Pharmaceuticals Group for the development of APL-2 in hematologic indications. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.

Current Quote*
Last: $29.780
Change: -0.230
Book: $11.989
Volume: 103,350

As Of: 08/22 13:19 ET
*Quotes delayed by 20min.

Graphs for APLS

3 Month Graph

6 Month Graph

1 Year Graph